PLUR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 21:30):

Stats
今日成交量	379.00
平均成交量	28 146.00
市值	33.68M
EPS	$0 ( 2024-05-08 )
下一个收益日期	( $0 ) 2024-06-25
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.350
ATR14	$0.178 (2.85%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Franco-yehuda Chen	Buy	355 000	Common Stock
2024-01-23	Aberman Zami	Buy	44 100	Common Stock
2024-01-23	Birger Pinhas Doron	Buy	39 900	Common Stock
2024-01-23	Shemesh-rasmussen Maital	Buy	38 150	Common Stock
2024-01-23	Yanay Yaky	Buy	700 000	Common Stock

INSIDER POWER
99.92
Last 95 transactions
Buy: 8 548 074 \| Sell: 1 004 814

Pluri Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Pluri Inc. 财务报表

Annual	2023
营收:	$287 000
毛利润:	$278 000 (96.86 %)
EPS:	$-6.18

FY	2023
营收:	$287 000
毛利润:	$278 000 (96.86 %)
EPS:	$-6.18

FY	2022
营收:	$234 000
毛利润:	$-41.36M (-17 674.79 %)
EPS:	$-1.270

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

Pluri Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Pluri Inc.

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

实时更新： Pluri Inc. [PLUR]

Upcoming Earnings Alert

Pluri Inc. Options Data

Calls

Puts